• Home
  • Site Map
  • Privacy Policy
    •
     
  • Continued Acid Control
  • Provide More Options for your Patients
  • Extensive Formulary Coverage
  • Information for Pharmacists
  • Tips and Tools
  • Prescribing Information
  • Consumer Website
    •
    ZEGERID is now a preferred oral PPI on many major health plans.3

    Print the ZEGERID Savings Coupon and help your patients start saving today!

    ZEGERID is the first and only immediate release oral PPI.

    View a video to see
    how ZEGERID works.

    Continued Acid Control vs Other Branded Prescription oral PPIs1-3

    Significantly greater nighttime acid control vs Prevacid® (lansoprazole)
    30 mg1 Continued nighttime acid control vs Nexium® (esomeprazole) 40 mg1

    • Only ZEGERID 40 mg*† maintains median pH>4
    Median Gastric pH
    • ZEGERID 40 mg*† achieved significantly greater median gastric pH than Prevacid
    • ZEGERID 40 mg*† maintains continued nighttime acid control

    The correlation of pharmacodynamic data to clinical effect has not been established.

    Median Percentage of time with gastric pH

    Pharmacodynamic study by Katz et al: open-label, randomized, crossover study evaluating nocturnal gastric acidity (N=49). Each patient received 7 consecutive QD bedtime doses (10 PM) of ZEGERID 40 mg Powder for oral Suspension, Prevacid 30 mg capsule, and Nexium 40 mg capsule. On Day 7, intragastric pH was recorded for 24 hours.1

    Significantly greater daytime acid control vs Prevacid 30 mg2

    Median 24 hour

    Pharmacodynamic study by Howden et al: open-label, randomized, crossover study evaluating 24-hour gastric acid control (N=51). Each patient received 7 consecutive QD morning doses (7 AM) of ZEGERID 40 mg Capsule, Prevacid 30 mg capsule, and Protonix 40 mg tablet. On Day 7, intragastric pH was recorded for 24 hours.

    The correlation of pharmacodynamic data to clinical effect has not been established.

    Significantly greater nighttime acid control vs Protonix® (pantoprazole) 40 mg3

    • Only ZEGERID 40 mg*† maintained median pH>4
    Noctural Median

    Pharmacodynamic study by Castell et al: open-label, randomized, crossover study evaluating nighttime gastric acidity (N=32). Each patient received consecutive QD bedtime doses (10 PM) of ZEGERID 40 mg Powder for oral Suspension and a QD bedtime dose (10 PM) on Day 1 followed by QD pre-dinner doses on Days 2 through 6 of Protonix 40 mg tablet.

    * Powder for oral suspension.

    † ZEGERID should be taken on an empty stomach at least 1 hour before a meal.

    § Capsule.

    ZEGERID should be used only for the conditions, dosages, and durations specified in the full prescribing information. Please see Important Safety Information.


    Next page: Effective in a Wide Range of Indications

    References
    1. Katz PO, Koch FK, Ballard ED, et al. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther. 2007;25:197-205.
    2. Howden CW, Ballard ED, Koch FK, Gautille TC, Bagin RG. Control of 24-hour Intragastric Acidity With Morning Dosing of Immediate-release and Delayed-release Proton Pump Inhibitors in Patients With GERD. J Clin Gastroenterol. 2008 Aug 28. [Epub ahead of print] PMID: 18758373.
    3. Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;21:1467-1474.

    Please see full prescribing information.

    You can obtain additional information about ZEGERID by writing Santarus directly. To speak to a representative by phone or to report an adverse event, call Santarus' Medical Information Department at 1.888.778.0887, option 2 (M-F, 9:00 am to 7:00 pm, EST).

    Product Description
    ZEGERID contains omeprazole, a proton pump inhibitor (PPI), and sodium bicarbonate, an antacid, which raises the gastric pH and thus protects omeprazole from acid degradation.

    Indications and Dosing for ZEGERID
    ZEGERID is indicated for heartburn and other symptoms associated with gastroesophageal reflux disease (GERD)
    (20 mg); for the short-term treatment (4-8 weeks) of erosive esophagitis diagnosed by endoscopy
    (20 mg); for maintenance of healing of erosive esophagitis (20 mg) (controlled studies do not extend beyond 12 months); for short-term treatment (4-8 weeks) of active duodenal ulcer (20 mg); for short-term treatment (4-8 weeks) of active benign gastric ulcer (40 mg); and for reduction of risk of upper gastrointestinal bleeding in critically ill patients (only powder for oral suspension 40 mg; use beyond 14 days has not been evaluated).

    Important Safety Information about ZEGERID
    The most frequently reported adverse events with ZEGERID are headache, diarrhea, and abdominal pain. In 178 critically ill patients treated with ZEGERID Powder for oral Suspension, adverse events generally reflected the serious, underlying medical condition of the patients, and were similar for patients treated with ZEGERID Powder for oral Suspension than in those treated with the comparator (acid-controlling) drug. For more information about these and other events, please see Table 4 of the Full Prescribing Information. Symptomatic response to therapy does not preclude the presence of gastric malignancy. Atrophic gastritis has been noted occasionally in gastric corpus biopsies from patients treated long term with omeprazole.

    ZEGERID Capsules contain 304 mg of sodium per dose. ZEGERID Powder for oral Suspension contains 460 mg of sodium per dose. This should be taken into consideration for patients on a sodium-restricted diet.

    Sodium bicarbonate is contraindicated in patients with metabolic alkalosis and hypocalcemia. ZEGERID is contraindicated in patients with known hypersensitivity to any component of the formulation.

    Since both 20 mg and 40 mg ZEGERID contain the same amount of sodium bicarbonate (1100 mg in capsules,
    1680 mg in packets of powder for oral suspension), two 20 mg capsules are not equivalent to, and should not be substituted for, one 40 mg capsule, and two 20 mg packets are not equivalent to, and should not be substituted for, one 40 mg packet.

    © 2010 Santarus, Inc. All rights reserved. 1-ZEG10046

    Use of this site constitutes your acceptance of our Terms of Use and Privacy Policy.